| P/E (FY) | — | Sales (TTM) | $41.9M |
| Earnings (TTM) | -$7.4M | ROE | −11.88% |
| Net Margin | −6.37% | ROIC | −19.36% |
| Debt / Equity | 0.00 | TD / EBITDA | 0.00 |
| EPS Growth 3Y | — | Sales Growth 3Y | 1.95% |
| Market Cap | $102.0M | Trading Days | 4263 |
| 52W High | 8.09 |
| 52W Low | 1.85 |
| % Off High | −15.82% |
| YTD | 71.11% | 1Y | 95.69% |
| 3Y | 350.99% | 5Y | 100.88% |
| 10Y | 44.89% | Since incept. (ann.) | −5.19% |
Non Us 100%
| Ann. Volatility (1Y) | 88.70% | Ann. Volatility (3Y) | 114.95% |
| Sharpe (1Y) | 1.20 | Sharpe (3Y) | 0.92 |
| Max Drawdown (1Y) | −52.62% | Max Drawdown (3Y) | −71.94% |
| Beta (3Y, vs SPY) | −0.62 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| IXHL | Incannex Healthcare Inc. | $102.0M | — |
| OGI | ORGANIGRAM GLOBAL INC. | $103.0M | — |
| ALDX | Aldeyra Therapeutics, Inc. | $95.3M | — |
| ONCY | ONCOLYTICS BIOTECH INC | $94.5M | — |
| COYA | Coya Therapeutics, Inc. | $93.8M | — |
| PLYX | Polaryx Therapeutics, Inc. | $92.8M | — |
| VRCA | Verrica Pharmaceuticals Inc. | $92.8M | — |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $92.0M | — |
| SPRB | SPRUCE BIOSCIENCES, INC. | $114.5M | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $90.8M | — |
| BMEA | Biomea Fusion, Inc. |
| $90.4M |
| — |
| ANIX | Anixa Biosciences Inc | $119.8M | — |
